Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Yuan-Yuan Qu,1,2 Zhongquan Sun,3 Weiqing Han,4 Qing Zou,5 Nianzeng Xing,6 Hong Luo,7 Xuepei Zhang,8 Chaohong He,9 Xiao-Jie Bian,1,2 Jinling Cai,10 Chunxia Chen,10 Quanren Wang,10 Ding-Wei Ye1,2

ABSTRACT

Background Dual blockade of immune checkpoint and angiogenesis is an effective strategy for multiple cancers. Camrelizumab is a monoclonal antibody against PD-1, and famitinib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenesis and antiproliferation activities against tumor cells. We conducted an open-label, multicenter phase 2 basket study of camrelizumab and famitinib in eight cohorts of genitourinary or gynecological cancers. Here, findings in cohort of advanced or metastatic urothelial carcinoma with platinum-progressive disease (cohort 2) are presented.

Methods Patients who had progressed after platinum-based chemotherapy for advanced or metastatic disease or had progressed within 12 months after completion of platinum-based (neo)adjuvant therapy were given camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1.

Results Totally, 36 patients were recruited. With a median duration from enrollment to data cut-off of 11.9 months (range 6.1–28.5), ORR was 30.6% (95% CI 16.3% to 48.1%). Median duration of response (DoR) was 6.3 months (95% CI 2.1 to not reached). Median progression-free survival (PFS) was 4.1 months (95% CI 2.2 to 8.2), and median overall survival (OS) was 12.9 months (95% CI 8.8 to not reached). Patients with bladder cancer (n=18) had numerically better outcomes, with an ORR of 38.9% (95% CI 17.3% to 64.3%) and a median PFS of 8.3 months (95% CI 4.1 to not reached). Median DoR and OS in this subpopulation had not been reached with lower limit of 95% CI of 4.2 months for DoR and 11.3 months for OS, respectively. Of 36 patients, 22 (61.1%) had grade 3 or 4 treatment-related adverse events, mainly decreased platelet count and hypertension.

Conclusions Camrelizumab plus famitinib showed potent antitumor activity in advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy. Patients with bladder cancer seemed to have better response to this combination.

Trial registration number NCT03827837.

BACKGROUND

Urothelial carcinoma is the most common urinary cancer worldwide that threatens the survival and quality of life. Despite local therapy, approximately one-third of patients will relapse and develop metastatic diseases.1,2 Additionally, about 5% of patients have distant metastases at initial diagnosis.3 Prognosis for patients with locally advanced or metastatic urothelial carcinoma is dismal. Platinum-based therapy is the current first-line standard of care. Around half of patients responded to cisplatin-containing or carboplatin-containing regimens, and the median overall survival (OS) was less than 16 months.4–8 During the preimmunotherapy era, second-line salvage chemotherapy only achieved tumor response in 8.6%–13.9% of patients and showed a median OS of
approximately 7 months. Since 2016, emergency of immune checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab, and avelumab monotherapy has revolutionized urothelial carcinoma care after failure of platinum-based chemotherapy, with 17%–21.1% of patients achieving an objective response and a median survival of 6.5–10.3 months.11 13 14 Nowadays, numerous combinatorial studies of an ICI with antiangiogenic agent or chemotherapy or two ICIs are conducting to further improve the outcomes.

Camrelizumab is a humanized monoclonal antibody against PD-1, which selectively blocks the PD-L1–PD-1 axis and eventually inhibits the immune escape of tumor cells.24 Famitinib is a multitargeted receptor tyrosine kinase inhibitor (TKI) that exhibits potent activities toward stem cell factor receptor (c-kit), VEGFR-2, and platelet-derived growth factor receptor β (PDGFRβ) with an IC50 value of 2.3, 4.7, and 6.6 nM, respectively, and also shows high inhibitory activities against other kinases including FMS-like tyrosine kinase-1/3 receptor (FLT1/3), VEGFR3, proto-oncogene tyrosine-protein kinase receptor (RET), and TAM family of kinases (AXL and MER).25 In addition to tumor angiogenesis and proliferation, these targets are involved in immune suppression pathways.26 Thus, famitinib has the potential to enhance the antitumor immune response to camrelizumab. In this context, we initiated a multicohort phase 2 study of camrelizumab and famitinib as monotherapy or combination therapy for genitourinary or gynecological cancers. Here, we present the results of camrelizumab plus famitinib in the cohort of checkpoint inhibitor-naïve, platinum-intensive pregnant patients with advanced or metastatic urothelial carcinoma (cohort 2).

METHODS

Study design and patients

This open-label, multicenter, basket phase 2 study of camrelizumab and famitinib was composed of eight cohorts in genitourinary or gynecological cancers. The overall study design had been published, and results for camrelizumab plus famitinib in the cohort of advanced or metastatic renal cell carcinoma (cohort 1) and cohort of platinum-resistant recurrent ovarian cancer (cohort 3) had been reported separately.21 22 In the cohort 2, eligible patients were aged 18–75 years, had pathological or cytological evidence of metastatic or surgically unresectable locally advanced urothelial carcinoma, had progression after platinum-based chemotherapy for advanced or metastatic disease or had progression within 12 months after completion of platinum-based adjuvant or neoadjuvant therapy, and had received one or two lines of systemic therapy for advanced or metastatic disease. Mixed histology that showed predominantly transitional-cell features was also eligible. Besides, patients should have an Eastern Cooperative Group performance status of 0 or 1, at least one measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, a life expectancy of 12 weeks or more, and adequate hematological, hepatic, and renal function. Key exclusion criteria included known active or a history of autoimmune disease; use of immunosuppressant or systemic hormone with 2 weeks before study; poorly controlled hypertension; untreated central nervous system metastases; radiological evidence of tumor invading major blood vessels; abnormal coagulation function, bleeding susceptibility or receiving thrombolysis or anticoagulation therapy. Prior chemotherapy within 4 weeks before study was not permitted. Prior surgery or palliative radiotherapy must be completed at least 2 weeks before study. Prior anti-PD-1/anti-PD-L1/anti-CTLA-4 antibodies was not allowed.

Procedures

Our previous data showed that camrelizumab 200 mg every 3 weeks by intravenous infusion combined with oral famitinib 20 mg once daily was well tolerated.23 Hence, all patients in this cohort received camrelizumab 200 mg every 3 weeks plus famitinib 20 mg once daily until confirmed disease progression (except quick radiological progression and clinical progression), unacceptable toxicity, patient decision or withdrawal of consent, withdrawal by the investigator, or lost to follow-up, whichever occurred first. Patients with RECIST-defined progression and a clinically stable status could continue study therapy at the discretion of the investigator. The maximum total camrelizumab exposure was 2 years. Interruptions of camrelizumab or famitinib and dose reductions of famitinib were permitted to manage toxic events.

Endpoints and assessments

The primary endpoint was objective response rate (ORR), defined as the percentage of patients with a best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST version 1.1. Secondary endpoints were disease control rate (DCR), time to response (TTR), duration of response (DoR), progression-free survival (PFS), OS, 12-month OS rate, and safety.

Tumor responses were assessed by the investigator, at baseline and then every three cycles, according to RECIST version 1.1. CRs or PRs were confirmed with a repeat scan at least 4 weeks after the initial response. After treatment discontinuation, patients were followed-up for survival status every 2 months. Vital sign, laboratory tests, 12-lead electrocardiograms, echocardiography, and adverse events (AEs) were monitored for safety assessments. AEs were assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (V.4.0) until 30 days after the last dose. Serious AEs (SAEs) and treatment-related AEs (TRAEs) were collected until 90 days after the last dose.

The PD-L1 was centrally tested using archival or fresh tumor tissues by PD-L1 HIC 22C3 pharmDx test (Dako, Carpinteria, California, USA). PD-L1 expression was calculated as Combined Positive Score (CPS), defined as
the number of PD-L1 staining cells (tumor cells, lymphocytes, and macrophages) out of the total number of tumor cells, multiplied by 100.

**Statistical analyses**

For this cohort, sample size was calculated using an adaptive two-stage design. An ORR of 15% was considered ineffective, 25% was considered low desirable response, and 35% was considered high desirable response. Assuming ORR as specified, a power of 80% for a high desirable response and 70% for a low desirable response, and a two-sided α level of 0.1, 22 patients would be enrolled at stage one; at stage two, enrollment would be terminated or extended to 53 or 33 depending on the observed response rate at stage one. Study treatment was considered effective if at least 12 of the 53 patients or at least 8 of the 33 patients responded.

At stage 1, 7 of the 22 patients in this cohort achieved objective responses, and thus enrollment of stage two was initiated. Efficacy was assessed in all patients with at least one dose of the study treatment. Safety was assessed in all patients who received at least one dose of study treatment and had at least one post-baseline assessments. ORR and DCR were calculated with their 95% CIs being estimated by the Clopper-Pearson method. Time-to-event endpoints including TTR, DoR, PFS, and OS were estimated with the Kaplan-Meier method, with the 95% CIs for median being calculated with the Brookmeyer and Crowley method and the 95% CIs for survival rates being calculated by means of log-log transformation (on the basis of normal approximation) with back transformation to CIs on the untransformed scale.

**RESULTS**

**Patient disposition and baseline characteristics**

From January 23, 2019 to December 14, 2020, a total of 36 patients with urothelial carcinoma from eight study sites in China were enrolled and treated with camrelizumab combined with famitinib. Median patient age was 62.5 years (range 43.0–79.0), and 28 (77.8%) patients were males (Table 1). Primary tumors were commonly found in the urinary bladder (n=18, 50.0%), followed by the renal pelvis (n=10, 27.8%). Twenty (55.6%) patients had at least two sites of metastases; and the most common metastasis site was lung (n=17, 47.2%). All patients had received platinum-based therapy.

As of June 8, 2021, the median follow-up duration from enrollment to data cut-off was 11.9 months (range, 6.1–28.5). The median cycle of camrelizumab received by patients was 10 (range 2–36), and the median exposure of famitinib was 28.4 weeks (range, 1.9–111.6). At the time of data cut-off, 11 (30.6%) patients were still receiving study treatment. The most common reason for discontinuation was disease progression (n=19, 52.8%), followed by withdrawal by patients, investigator decision, and AEs (n=2, 5.6% for each).

---

**Table 1** Patient demographics and baseline characteristics

| Characteristics                                      | Patients (N=36) |
|------------------------------------------------------|-----------------|
| Median age (range), years                            | 62.5 (43.0–79.0) |
| Sex                                                  |                 |
| Male                                                 | 28 (77.8%)      |
| Female                                               | 8 (22.2%)       |
| ECOG performance status                              |                 |
| 0                                                    | 11 (30.6%)      |
| 1                                                    | 25 (69.4%)      |
| No. of organs of metastases                          |                 |
| 1                                                    | 14 (38.9%)      |
| 2                                                    | 6 (16.7%)       |
| >2                                                   | 14 (38.9%)      |
| Common visceral diseases                              |                 |
| Lung metastases                                      | 17 (47.2%)      |
| Bone metastases                                      | 8 (22.2%)       |
| Liver metastases                                     | 8 (22.2%)       |
| Subsite of primary tumor                             |                 |
| Bladder                                              | 18 (50.0%)      |
| Renal pelvis                                         | 10 (27.8%)      |
| Ureter                                               | 5 (13.9%)       |
| Mixed                                                | 2 (5.6%)        |
| Urethra                                              | 1 (2.8%)        |
| Prior surgery for primary tumor                      |                 |
| 29 (80.6%)                                           |
| Prior platinum-based therapies                       | 36 (100%)       |
| Adjuvant therapy                                     | 1 (2.8%)        |
| One line                                             | 31 (86.1%)      |
| Two lines                                            | 4 (11.1%)       |
| Previous systemic therapy                            |                 |
| Platinum in neoadjuvant or adjuvant settings*         | 2 (5.6%)        |
| Platinum in advanced or metastatic settings          | 35 (97.2%)      |
| Cisplatin-based regimen only                         | 24 (66.7%)      |
| Carboplatin-based regimen only                       | 4 (11.1%)       |
| Both cisplatin-based and carboplatin-based regimens  | 1 (2.8%)        |
| Other platinum-based regimen                         | 6 (16.7%)       |
| PD-L1 CPS in 27 evaluable patients                   |                 |
| <1                                                   | 19 (70.4%)      |
| ≥1                                                   | 8 (29.6%)       |

Data are n (%) unless stated otherwise.

*One patient had received platinum-based regimen both in neoadjuvant or adjuvant setting and advanced or metastatic setting.

CPS, Combined Positive Score; ECOG, Eastern Cooperative Group.

**Efficacy in all patients**

As shown in figure 1A, 21 of the 33 (63.6%) patients who had postbaseline target lesion assessment showed
Tumor responses in all 36 patients were summarized in table 2. Objective response was achieved in 30.6% (95% CI 16.3% to 48.1%) of patients, including one (2.8%) CR and 10 (27.8%) PRs. Stable disease was observed in 12 (33.3%) patients, and DCR was 63.9% (95% CI 46.2% to 79.2%).

Of the 11 responders, the responses were ongoing in 5 (45.5%) patients (figure 1B). The median DoR was 6.3 months (95% CI 2.1 to not reached), and DoR rate at 6 months was 72.7% (95% CI 37.1% to 90.3%). The median TTR was 2.1 months (range 1.9–2.1). Of the 11 responders, the responses were ongoing in 5 (45.5%) patients (figure 1B). The median DoR was 6.3 months (95% CI 2.1 to not reached), and DoR rate at 6 months was 72.7% (95% CI 37.1% to 90.3%). The median TTR was 2.1 months (range 1.9–2.1).

As of cut-off date, 26 (72.2%) events of disease progression or deaths occurred. The median PFS was 4.1 months (95% CI 2.2 to 8.2; figure 2A), and PFS rate at 6 months was 45.4% (95% CI 28.5% to 60.8%). There were 14 (38.9%) deaths occurred. The median OS was 12.9 months (95% CI 8.8 to not reached; figure 3A), and 12-month OS rate was 56.0% (95% CI 35.0% to 72.6%).

**Efficacy in subgroup by the primary tumor type**

ORR was 38.9% (95% CI 17.3% to 64.3%) in the 18 patients with bladder cancer vs 22.2% (95% CI 6.4% to 47.6%) in the 18 patients with other urothelial cancer, and DCR was 77.8% (95% CI 52.4% to 93.6%) vs 50.0% (95% CI 26.0% to 74.0%), respectively (table 2).
At the time of data cut-off, four of seven (57.1%) responders in the bladder cancer subgroup and one of four (25.0%) responders in the other urothelial cancer subgroup continued to have a response. The median DoR in patients with bladder cancer had not been reached yet (95% CI 4.2 to not reached), while in patients with other urothelial cancers, the median DoR was 4.2 months (95% CI 2.1 to not reached). Six-month DoR rate was 85.7% (95% CI 33.4% to 97.9%) versus 50.0% (95% CI 5.8% to 84.5%). The median TTR was similar between the bladder cancer and other urothelial cancer subgroups (table 2).

A total of 10 (55.6%) and 16 (88.9%) events of disease progression or death occurred in the bladder cancer and other urothelial cancer subgroups. The median PFS was 8.3 months (95% CI 4.1 to not reached) vs 3.1 months (95% CI 2.1 to 4.1; figure 2B), and 6-months PFS rate was 70.6% (95% CI 43.1% to 86.6%) vs 22.2% (95% CI 6.9% to 42.9%), respectively. Four (22.2%) patients with bladder cancer and 10 (55.6%) with other urothelial cancer died at cut-off date. The median OS had not been reached yet (95% CI 11.3 to not reached) in the bladder cancer subgroup and was 8.8 months (95% CI 5.5 to not reached) in the other urothelial cancer subgroup (figure 3B), and OS rate at 12 months was 64.3% (95% CI 27.2% to 86.1%) and 44.3% (95% CI 19.8% to 66.4%), respectively.

### Efficacy in subgroup by PD-L1 expression

Tumor biospecimens of 27 patients were available for PD-L1 expression assessment. Eight patients had PD-L1 CPS ≥1. ORR was 37.5% (95% CI 8.5% to 75.5%) in patients with PD-L1 CPS ≥1 and 31.6% (95% CI 12.6% to 56.6%) in patients with PD-L1 CPS<1.

### Safety

TRAEs of any grade occurred in all 36 patients (table 3), with the most common ones being proteinuria (n=25, 69.4%), decreased platelet count (n=24, 66.7%), anemia (n=20, 55.6%), palmar-plantar erythrodysesthesia (PPE) syndrome (n=15, 41.7%), and decreased white blood cell count (n=15, 41.7%). A total of 17 (47.2%) patients experienced grade 3 TRAEs; those occurring in more than 10% of patients were decreased platelet count and hypertension (n=5 each, 13.9%). Five (13.9%) patients had grade 4 TRAEs (decreased platelet count, n=2, 5.6%; hyperuricemia, n=2, 5.6%; increased blood creatinine, n=1, 2.8%).

Treatment-related SAEs occurred in seven (19.4%) patients (online supplemental table S1), including decreased platelet count (n=3, 8.3%) and multiple organ dysfunction syndrome, pyrexia, immune-mediated hepatitis, reactive capillary endothelial proliferation (RCEP), and myelosuppression (n=1 each, 2.8%). Totally, there were seven deaths due to AEs, among them only one was deemed to be treatment-related by the investigator. The patient died of multiple organ dysfunction syndrome.

One (2.8%) patient discontinued treatment because of TRAE (multiple organ dysfunction syndrome). TRAEs led to dose interruption of camrelizumab in 14 (38.9%) patients (online supplemental table S1), including decreased platelet count (n=3, 8.3%) and multiple organ dysfunction syndrome, pyrexia, immune-mediated hepatitis, reactive capillary endothelial proliferation (RCEP), and myelosuppression (n=1 each, 2.8%). Totally, there were seven deaths due to AEs, among them only one was deemed to be treatment-related by the investigator. The patient died of multiple organ dysfunction syndrome.

### Efficacy in subgroup by PD-L1 expression

Tumor biospecimens of 27 patients were available for PD-L1 expression assessment. Eight patients had PD-L1 CPS ≥1. ORR was 37.5% (95% CI 8.5% to 75.5%) in patients with PD-L1 CPS ≥1 and 31.6% (95% CI 12.6% to 56.6%) in patients with PD-L1 CPS<1.
to dose reduction of famitinib in nine (25.0%) patients, with PPE syndrome occurring in more than one patient.

Immune-related AEs (irAEs), regardless of whether they were attributed to study treatment by investigators, occurred in 6 (16.7%) of 36 patients, including hypothyroidism (n=2, 5.6%) and hyperthyroidism, autoimmune thyroiditis, immune-mediated hepatitis, immune-mediated hepatic disorder, pyrexia, asthenia, generalized edema, increased blood thyroid stimulating hormone, hypersensitivity, immune-mediated dermatitis, pruritus, and cheilitis (n=1 each, 2.8%).

RCEP was reported in 16.7% of patients (n=6). Majority of the events were grade 1 or 2 in severity (n=5, 13.9%), and only one (2.8%) patient had grade 3 RCEP.

**DISCUSSION**

In this phase 2 study, camrelizumab combined with famitinib was associated with promising antitumor activity in patients with advanced or metastatic urothelial carcinoma after platinum-based therapy, with an ORR of 30.6% (95% CI 16.3% to 48.1%), a median PFS of 4.1 months (95% CI 2.2 to 8.2), and a median OS of 12.9 months (95% CI 8.8 to not reached).

Urothelial carcinomas are considered immunogenic with high PD-L1 expression level and high somatic mutation burden, providing a theoretical basis for immunotherapy. In the clinical studies of ICI monotherapy after platinum-based therapy, pembrolizumab achieved tumor response in 21.1% (95% CI 16.4% to 26.5%) of patients, nivolumab in 19.6% (95% CI 15.0% to 24.9%), and avelumab in 17% (95% CI 11% to 24%).

The proportion of patients respond to camrelizumab plus famitinib compared favorably with those reported data (approximately 10% higher). Of note, urothelial bladder cancer accounted for over 70% of patients enrolled in these studies of ICI monotherapy. Response
to pembrolizumab or avelumab in this subpopulation with bladder cancer was not available; the ORR with nivolumab was 22% (95% CI 16% to 28%). In our study, 50.0% of the enrolled patients had urothelial carcinoma of bladder and exhibited an ORR of 38.9% (95% CI 17.3% to 64.3%). Our findings indicted antiangiogenic TKI famitinib as an attractive drug when combined with camrelizumab to augment immunotherapy response in urothelial carcinoma, especially in bladder cancer.

Shorter median DoR was indicated with PD-1 inhibitor combined with TKI compared with PD-1 inhibitor monotherapy (6.3 months with camrelizumab plus famitinib and 8.3 months with pembrolizumab plus ramucirumab), which might because some responders mainly benefited from the TKI considering that only 5.1 months or less was achieved by TKI alone. However, more patients responded to the combination, bringing prolonged survival benefit. In patients with advanced or metastatic urothelial carcinoma after platinum-based therapy, the median PFS was 2.1 months (95% CI 2.0 to 2.2) with pembrolizumab, 2.00 months (95% CI 1.87 to 2.63) with nivolumab, and 6.3 weeks (95% CI 6.0 to 10.1) with avelumab, with no improvement compared with historical data with single-drug chemotherapies in this setting. By combining with an antiangiogenic agent, camrelizumab plus famitinib attained a favorable median PFS of 4.1 months (95% CI 2.2 to 8.2). Also, clinical meaningful improvement in OS was observed (median, 12.9 months (95% CI 8.8 to not reached) with camrelizumab plus famitinib compared with 6.5–10.3 months with avelumab, nivolumab, or pembrolizumab). Notably, in the subpopulation with bladder cancer in our study, the median PFS was as high as 8.3 months (95% CI 4.1 to not reached), and the median OS had not been reached with lower limit of 95% CI of 11.3 months.

While upper-tract urothelial carcinoma (UTUC) share similar histological appearance with bladder urothelial carcinoma, they have differences in etiology,

---

**Figure 3** Kaplan-Meier estimates of overall survival. (A) All patients; (B) subgroup by primary tumor types. NR, not reached.
clinical phenotype, and molecular alterations. UTUC is a rare malignancy associated with an aggressive phenotype. About 60% of UTUC patients have muscle invasive disease at diagnosis and nearly 25% have regional metastasis.\textsuperscript{29-31} Asian patients seem to present with more advanced and higher-grade diseases compared with other ethnicities,\textsuperscript{32} which might enlarge the distinct outcomes of UTUC and bladder urothelial carcinoma in our study.

Tumor genomic analysis showed higher FGFR3 alterations in UTUC patients, and these patients could potentially benefit from FGFR3-targeted therapy.\textsuperscript{33} Patients with bladder urothelial carcinoma had higher PD-L1 than those with UTUC and thus were more likely to benefit from immunotherapy.\textsuperscript{33}

Early-phase clinical trials have explored combinations in patients with advanced or metastatic urothelial carcinoma in the second-line setting. In a multicohort phase 1a/b trial of ramucirumab plus pembrolizumab, despite manageable safety profile, no obviously favorable antitumor efficacy over ICI monotherapy was observed.

### Table 3  Summary of TRAEs

| TRAEs                                      | All patients (N=36) |
|--------------------------------------------|---------------------|
| Any grade                                  | 36 (100.0%)         |
| Grade 3                                    | 17 (47.2%)          |
| Grade 4                                    | 5 (13.9%)           |
| Serious                                    | 7 (19.4%)           |

| TRAEs leading to                           |                     |
|--------------------------------------------|---------------------|
| Camrelizumab interruption                  | 14 (38.9%)          |
| Camrelizumab discontinuation               | 1 (2.8%)            |
| Famitinib dose reduction/interruption      | 21 (58.3%)          |
| Famitinib interruption                     | 20 (55.6%)          |
| Famitinib dose reduction                   | 9 (25.0%)           |
| Famitinib discontinuation                  | 1 (2.8%)            |
| Deaths                                     | 1 (2.8%)            |

| Common TRAEs*                              | Any grade | Grade 3 | Grade 4 |
|--------------------------------------------|-----------|---------|---------|
| Proteinuria                                | 25 (69.4%)| 2 (5.6%)| 0       |
| Platelet count decreased                   | 24 (66.7%)| 5 (13.9%)| 2 (5.6%)|
| Anemia                                     | 20 (55.6%)| 3 (8.3%)| 0       |
| PPE syndrome                               | 15 (41.7%)| 3 (8.3%)| 0       |
| WBC count decreased                        | 15 (41.7%)| 1 (2.8%)| 0       |
| Hypertension                               | 13 (36.1%)| 5 (13.9%)| 0       |
| Blood creatinine increased                 | 11 (30.6%)| 0       | 1 (2.8%)|
| Neutrophil count decreased                 | 11 (30.6%)| 1 (2.8%)| 0       |
| Diarrhea                                   | 11 (30.6%)| 1 (2.8%)| 0       |
| ALT increased                              | 10 (27.8%)| 1 (2.8%)| 0       |
| Askenia                                    | 10 (27.8%)| 0       | 0       |
| AST increased                              | 9 (25.0%)| 0       | 0       |
| Decreased appetite                         | 9 (25.0%)| 0       | 0       |
| Hyperuricemia                              | 7 (19.4%)| 1 (2.8%)| 2 (5.6%)|
| GGT increased                              | 7 (19.4%)| 2 (5.6%)| 0       |
| Hypertriglyceridemia                       | 6 (16.7%)| 1 (2.8%)| 0       |
| RCEP                                       | 6 (16.7%)| 1 (2.8%)| 0       |
| Blood pressure increased                   | 6 (16.7%)| 0       | 0       |
| Hypokalemia                                | 4 (11.1%)| 2 (5.6%)| 0       |

Data are shown in n (%).

*TRAEs of all grades occurring in at least 15% of patients, grade 3 TRAEs occurring in at least 5% of patients, and all grade 4 TRAEs are listed. One patient died due to TRAE, multiple organ dysfunction syndrome.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; PPE, palmar-plantar erythrodysesthesia; RCEP, reactive capillary endothelial proliferation; TRAE, treatment-related adverse event; WBC, white blood cell.
(ORR, 13% (95% CI 2.7 to 32.4); median PFS, 1.9 months (95% CI 1.2 to 2.8); median OS, 6.4 months (95% CI 2.5 to 18.7)). In two phase 2 studies involving combination of small-molecule TKI and ICI in cohort of in urothelial carcinoma, encouraging efficacy was reported. Lenvatinib plus pembrolizumab showed an ORR of 25% (95% CI 8.7% to 49.1%) and median PFS of 5.4 months (95% CI 1.3 to not reached).56 and cabozantinib plus durvalumab had an ORR of 37.5% (95% CI 15.2% to 64.6%).56 Our findings were comparable to these released data.

There are two phase 3 studies of the combinations as front-line treatment for urothelial carcinoma. The LEAP-011 study (NCT03898180) of first-line pembrolizumab plus lenvatinib was stopped early. In patients who were cisplatin-ineligible with PD-L1-positive tumors (CPS ≥10) or were ineligible to receive any platinum-based chemotherapy, no significant differences in median PFS and OS were found between pembrolizumab plus lenvatinib and pembrolizumab plus placebo.37 The MAIN-CAV study (NCT05092958) of maintenance cabozantinib plus avelumab after first-line platinum-based chemotherapy is ongoing and the results are expected.

Data from clinical trials of ICI monotherapy showed inconsistent results in terms of associations between response and PD-L1 expression in urothelial carcinoma, which may be caused by differences in procedure of tissue collection and fixation, antibody and assay used for PD-L1 test, definition of PD-L1 expression, and cut-off for PD-L1 positivity. For combination therapy, there was also no evidence supporting the use of PD-L1 as a biomarker in urothelial carcinoma.34-36 In this study, antitumor responses were seen irrespective of PD-L1 expression, even patients with PD-L1 CPS<1 achieved an ORR of 31.6% (95% CI 12.6% to 56.6%).

In line with our findings in the cohorts of advanced or metastatic renal cell carcinoma and ovarian cancer,21 22 no new safety concerns with camrelizumab plus famitinib were found in patients with advanced or metastatic urothelial carcinoma. Generally, with median duration from enrollment of 11.9 months, camrelizumab 200 mg every 3 weeks plus famitinib 20 mg once daily were tolerable and the AEs were manageable.

Most AEs that mainly attributed to famitinib such as proteinuria, hypertension, PPE syndrome, and hematological toxicities38–40 could be controlled by treatment interruption. Only 25% of patients had unsolved AEs that needed to reduce the dose of famitinib.

RCEP is the most common AE attributable to camrelizumab monotherapy occurring in 67%–97.3% of the patients in previous studies, but majority of them were grade 1 (nodules with a maximum diameter of ≤10 mm) or grade 2 (nodules with a maximum diameter of >10 mm) in severity.15 41–46 The events mainly occurred on skin of the head, face, and trunk, and most lesions were scattered on the skin, which was different from other common skin irAE such as rash. According to the morphology, RCEP could be divided into five types including ‘red-nevuslike’ ‘pearl-like’ ‘mulberry-like’ ‘patch-like’ and ‘tumor-like’, with the first two being the most common types.47 Growth of RCEP experienced a tripartite cycle of proliferation, plateau, and involution, and most lesions spontaneously resolved after discontinuation of camrelizumab. When combined with famitinib, only 16.7% of urothelial carcinoma patients in this study experienced RCEP. This was consistent with other studies involving camrelizumab in combination with a VEGFR inhibitor.21 22 48 49 It has been speculated that camrelizumab-induced reactivation of the immune response disrupts the balance between proangiogenic and anti-angiogenic growth factors, finally promoting vascular proliferation by releasing VEGF-A.47 Thus, combination with famitinib might inhibit the development of RCEP by blocking VEGF signal transduction.

Only one (2.8%) patient discontinued treatment owing to TRAE. The patient was male aged 64 years and had high-grade urothelial carcinoma of the ureter. He received two cycles of camrelizumab plus famitinib and died for multiple organ dysfunction syndrome that was judged possibly related to study treatment by investigator. But the possible reason for death was noted to be progressive disease. As there are no reported evidence of causality between multiple organ dysfunction syndrome and camrelizumab or famitinib, and no deaths due to multiple organ dysfunction syndrome occurred in other cohorts of this study, further assessment is required.

Due to the exploratory nature of this phase 2 study, the major limitation of this study is lack of a control arm. It is hard to contextualize our findings relative to approved ICI monotherapy. Besides, due to small sample size, bladder cancer and PD-L1 subgroup findings need further investigation. Aside from PD-L1 expression, translational and biomarker analyses were not done as it was not mandatory for patients to provide the tumor sample. A company-sponsored, randomized, controlled phase 3 clinical trial is planning to assess this combination in patients with untreated advanced or metastatic urothelial carcinoma and to explore candidate prognostic biomarkers.

In conclusion, this study demonstrated the promising clinical activity and controllable safety of camrelizumab combined with famitinib in patients with advanced or metastatic urothelial carcinoma after platinum-based therapy. Patients with bladder cancer seemed to have better response to this combination. Our findings support further investigation of this combination in large-scale phase 3 study.

**Author affiliations**

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3Department of Urology Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China
4Department of Urology Surgery, Hunan Cancer Hospital, Changsha, China
5Department of Urology Surgery, Jiangsu Cancer Hospital, Nanjing, China
6Department of Urology Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
7Department of Urology Surgery, Chongqing Cancer Hospital, Chongqing, China
8Department of Urology Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Qu Y-Y, et al. J Immunother Cancer 2022;10:e004427. doi:10.1136/jitc-2021-004427
Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

Acknowledgements We thank all patients and their families, investigators, and research personnel for participating in this study. Writing assistance was provided by Hui Dong (PhD, a Medical Writer from Jiangsu Hengrui Pharmaceuticals) according to Good Publication Practice Guidelines.

Contributors DY was responsible for the overall content as guarantor; DY and QW contributed to study design and conception; YQ, ZS, WH, QZ, NX, HL, XZ, CH and XB contributed to patient recruitment and data acquisition; CC contributed to statistical analysis. DY, YQ and QW contributed to interpretation of the data. DY, YQ, JC and CC wrote the initial manuscript. All authors read and approved the final manuscript.

Funding This work was sponsored by Jiangsu Hengrui Pharmaceuticals and partly supported by grants from the National Key Research and Development Project (No. 2019YFC1316000) and Shanghai Municipal Health Bureau (No. 2020ZX003).

Competing interests JC, CC, and QW are employees of Jiangsu Hengrui Pharmaceuticals. No other potential conflicts of interest were reported.

Patient consent for publication Not applicable.

Ethics approval The protocol was approved by the Ethics Committee of each participating site, as well as all amendments. Each patient provided the written informed consent. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and local laws and regulatory requirements. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Data are available on reasonable request. The data that support the findings of this study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75.
2. Tripathi A, Plimack ER. Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep 2018;19:109.
3. Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review, 1975-2018. Bethesda, MD: National Cancer Institute, 2020. https://seer.cancer.gov/csr/1975_2018/
4. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–77.
5. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol No. 30924. J Clin Oncol 2001;19:2638–46.
6. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–8.
7. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–4.
8. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblinatine in patients with advanced urothelial carcinoma who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191–9.
9. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454–61.
10. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2020;21:105–20.
11. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26.
12. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–57.
13. Sharma P, Retz M, Sieffer-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol 2018;19:312–22.
14. Patel MR, Elerton J, IR, et al. Irinotecan in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64.
15. Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 2018;119:538–45.
16. Lou L, Mi Y, Xu Y. Preclinical anti-tumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR/PDGFRα/KIT-in phase I clinical trials. AACR, 2011.
17. Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 2018;9:978.
18. Almand B, Clark JJ, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2003;166:678-89.
19. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–22.
20. Gnarawal S, Ganguly S, Hajian P, et al. PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget 2015;6:28621–32.
21. Qu Y-Z, Zhang H-L, Guo H, et al. Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase II basket study. Cancer Res Clin Oncol 2021;27:2838-46.
22. Xia L, Peng J, Lou G, et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer 2022;10:e003831.
23. Wu X, Xia L, Zhang Y. Farnitbinib malate plus camrelizumab in patients with recurrent platinum-resistant ovarian, Fallopian tube or primary peritoneal cancer: A multicenter, open-label, single-arm, phase II trial. In SGO 2020 Annual Meeting on Women’s Cancer. SGO 2020.
24. Lin Y, Shih WJ. Adaptive two-stage design of a single-arm phase IIa cancer clinical trials. Biometrics 2004;60:482–90.
25. Boorjian SA, Sheinin Y, Crispin PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008;14:4800–8.
26. Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 2015;85:703.e1–703.e6.
27. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomatous: associations with localized stage progression. Cancer 2007;105:1499–505.
28. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373–9.
29. Chen X, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2012;61:818–25.
30 Stewart GD, Bariol SV, Grigor KM, et al. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. *BJU Int* 2005;95:791–3.

31 Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World J Urol* 2017;35:379–87.

32 Matsumoto K, Novara G, Gupta A, et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int* 2011;108:E304–9.

33 Yang K, Yu W, Liu H, et al. Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder. *Oncologist* 2021;26:e1395–405.

34 Herbst RS, Arkenau H-T, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. *Lancet Oncol* 2019;20:1109–23.

35 Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. *J Clin Oncol* 2020;38:1154–63.

36 Marandino L, Raggi D, Calareso G, et al. Cabozantinib plus Durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 Arcadia trial. *Clin Genitourin Cancer* 2021;19:457–65.

37 Loriot Y, Grivas P, De Witt R. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. In ASCO Genitourinary Cancer Symposium. *American Society of Clinical Oncology* 2022.

38 Xu R-H, Shen L, Wang K-M, et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. *Chin J Cancer* 2017;36:97.

39 Zhou A, Zhang W, Chang C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. *Cancer Chemother Pharmacol* 2013;72:1043–53.

40 Zhang W, Zhou A-P, Qin Q, et al. Famitinib in metastatic renal cell carcinoma: a single center study. *Chin Med J* 2013;126:4277–81.

41 Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. *Clin Cancer Res* 2018;24:1296–304.

42 Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. *Cancer* 2019;125:742–9.

43 Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. *Lancet Oncol* 2018;19:1338–50.

44 Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. *J Clin Oncol* 2019;37:1479–89.

45 Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. *Lancet Oncol* 2020;21:571–80.

46 Song Y, Wu J, Chen X, et al. A single-arm, multicenter, phase II study of Camrelizumab in relapsed or refractory classical Hodgkin lymphoma. *Clin Cancer Res* 2019;25:7363–9.

47 Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. *J Hematol Oncol* 2020;13:47.

48 Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. *Clin Cancer Res* 2019;25:515–23.

49 Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (rescue): a nonrandomized, open-label, phase II trial. *Clin Cancer Res* 2021;27:1003–11.